Thomas Monfeuga
Research Subjects
Thomas Monfeuga has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Alina Griebel
Institute of Pharmacology and Toxicology, Technical University Munich (TUM), Munich, Germany
2 shared publications- Ana I. Domingos
Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK
2 shared publications Anandhakumar Chandran
Research and Development, Novo Nordisk Research Centre Oxford, Oxford, UK
2 shared publicationsAndrea Raimondi
Experimental Imaging Centre, IRCCS San Raffaele Scientific Institute, Milan, Italy
2 shared publicationsBernardo A. Arús
Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany
2 shared publicationsCyrielle Maroteau
Research and Development, Novo Nordisk Research Centre Oxford, Oxford, UK
2 shared publications
Latest Publications
- Open Access
- 11 August 2026
- Published by Springer Nature in Nature Metabolism
- Vol. 8 (9) , 2038
Author Correction: The perineurium integrates leptin with its sympathetic outflow to protect against obesity
- 11 August 2026
- Published by Springer Nature in Nature Metabolism
- Vol. 8 (9) , 2038
Open AccessAuthor Correction: The perineurium integrates leptin with its sympathetic outflow to protect against obesity
- Open Access
- 13 July 2026
- Published by Springer Nature in Nature Metabolism
- Vol. 8 (7) , 1563-1582
The perineurium integrates leptin with its sympathetic outflow to protect against obesity
The regulatory mechanism of leptin’s afferent action in the brain is contingent upon the efferent sympathetic innervation of white and brown adipose tissues. Nonetheless, the peripheral regulation governing the afferent–efferent balance remains ambiguous. Here we show the enriched expression of both leptin receptor ( Lepr ) and β 2 -adrenergic receptor ( Adrb2 ) in perineurial cells that form a barrier around sympathetic ganglia and nerve bundles in adipose tissues, using single-cell RNA sequencing on mouse sympathetic ganglia. Lepr + sympathetic perineurial cells (SPCs) are molecularly similar to endothelial cells. Conditional knockout of Adrb2 in Lepr + cells, including SPCs, predisposes male mice to obesity by lowering energy expenditure and thermogenesis without affecting food intake. Notably, obesity-associated hyperleptinaemia causes apoptosis in SPCs, disrupting the perineurial barrier and concomitant adipose sympathetic neuropathy. This deleterious effect can be reversed by partial reduction of leptin or sympathomimetic β 2 -adrenergic receptor agonism. Clinically, we observed a male-specific synergistic effect of LEPR and ADRB2 polymorphisms on increased body mass index risk in a large European population. We propose that SPCs coordinate the afferent and efferent arms of the neuroendocrine loop of leptin action to regulate energy expenditure and body weight.
- 13 July 2026
- Published by Springer Nature in Nature Metabolism
- Vol. 8 (7) , 1563-1582
Open AccessThe perineurium integrates leptin with its sympathetic outflow to protect against obesity
The regulatory mechanism of leptin’s afferent action in the brain is contingent upon the efferent sympathetic innervation of white and brown adipose tissues. Nonetheless, the peripheral regulation governing the afferent–efferent balance remains ambiguous. Here we show the enriched expression of both leptin receptor ( Lepr ) and β 2 -adrenergic receptor ( Adrb2 ) in perineurial cells that form a barrier around sympathetic ganglia and nerve bundles in adipose tissues, using single-cell RNA sequencing on mouse sympathetic ganglia. Lepr + sympathetic perineurial cells (SPCs) are molecularly similar to endothelial cells. Conditional knockout of Adrb2 in Lepr + cells, including SPCs, predisposes male mice to obesity by lowering energy expenditure and thermogenesis without affecting food intake. Notably, obesity-associated hyperleptinaemia causes apoptosis in SPCs, disrupting the perineurial barrier and concomitant adipose sympathetic neuropathy. This deleterious effect can be reversed by partial reduction of leptin or sympathomimetic β 2 -adrenergic receptor agonism. Clinically, we observed a male-specific synergistic effect of LEPR and ADRB2 polymorphisms on increased body mass index risk in a large European population. We propose that SPCs coordinate the afferent and efferent arms of the neuroendocrine loop of leptin action to regulate energy expenditure and body weight.
- Top Cited PapersOpen Access
- 1 April 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-17
Data-driven identification of predictive risk biomarkers for subgroups of osteoarthritis using interpretable machine learning
Osteoarthritis (OA) is increasing in prevalence and has a severe impact on patients’ lives. However, our understanding of biomarkers driving OA risk remains limited. We developed a model predicting the five-year risk of OA diagnosis, integrating retrospective clinical, lifestyle and biomarker data from the UK Biobank (19,120 patients with OA, ROC-AUC: 0.72, 95%CI (0.71–0.73)). Higher age, BMI and prescription of non-steroidal anti-inflammatory drugs contributed most to increased OA risk prediction ahead of diagnosis. We identified 14 subgroups of OA risk profiles. These subgroups were validated in an independent set of patients evaluating the 11-year OA risk, with 88% of patients being uniquely assigned to one of the 14 subgroups. Individual OA risk profiles were characterised by personalised biomarkers. Omics integration demonstrated the predictive importance of key OA genes and pathways (e.g., GDF5 and TGF-β signalling) and OA-specific biomarkers (e.g., CRTAC1 and COL9A1). In summary, this work identifies opportunities for personalised OA prevention and insights into its underlying pathogenesis.
- 1 April 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-17
Top Cited PapersOpen AccessData-driven identification of predictive risk biomarkers for subgroups of osteoarthritis using interpretable machine learning
Osteoarthritis (OA) is increasing in prevalence and has a severe impact on patients’ lives. However, our understanding of biomarkers driving OA risk remains limited. We developed a model predicting the five-year risk of OA diagnosis, integrating retrospective clinical, lifestyle and biomarker data from the UK Biobank (19,120 patients with OA, ROC-AUC: 0.72, 95%CI (0.71–0.73)). Higher age, BMI and prescription of non-steroidal anti-inflammatory drugs contributed most to increased OA risk prediction ahead of diagnosis. We identified 14 subgroups of OA risk profiles. These subgroups were validated in an independent set of patients evaluating the 11-year OA risk, with 88% of patients being uniquely assigned to one of the 14 subgroups. Individual OA risk profiles were characterised by personalised biomarkers. Omics integration demonstrated the predictive importance of key OA genes and pathways (e.g., GDF5 and TGF-β signalling) and OA-specific biomarkers (e.g., CRTAC1 and COL9A1). In summary, this work identifies opportunities for personalised OA prevention and insights into its underlying pathogenesis.